Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases

2026/06/01 by Zara Siu Wa Chui, Yaqian Xue, Xiaoping Wu +1
Medicine · Neuroscience · #Diabetes Treatment and Management #Regulation of Appetite and Obesity #Growth Hormone and Insulin-like Growth Factors

paper · doi:10.1016/j.pharmr.2026.100150

Citations

• ドコみる? どうみる? フットケア誌上検討会--症例・写真をみてアセスメントにチャレンジ!(CASE 5)どこをみますか? 何がわかりますか? どうケアしますか?
• FGF21 attenuates lipolysis in human adipocytes – A possible link to improved insulin sensitivity
• Different roles of N‐ and C‐ termini in the functional activity of FGF21
• Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
• Tirzepatide: A Review in Type 2 Diabetes
• Global burden of metabolic diseases, 1990–2021